Cancer

NanoViricides Provides Additional Details on the Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola as the Outbreak Continues to Expand and Has Taken Over 4,000 Lives

Cosmos Health’s Brands Reach More Than 40 Countries Across Europe, the Middle East, North America and Asia, Addressing Global Markets Estimated at Approximately $946 Billion

More than 15 proprietary brands and product lines, plus 10 branded generics - across nutraceuticals, infection control, advanced formulations, skin...

Valion Bio and Shear Kershman Laboratories Successfully Formulate Oral Mucosal Entolimod; Valion Sees Potential for Multi-Fold Expansion of Long-Term Opportunity

Needle-free program creates a potential second development pathway alongside Valion's injectable Entolimod programNext study will test whether the formulation delivers...

error: Content is protected !!